Advocates encourage prioritization of drug-resistant TB research

TB advocates encourage the Global Antimicrobial Resistance Innovation Fund to prioritize research and development for drug-resistant TB.

In an open letter sent to the Global Antimicrobial Resistance Innovation Fund on 19 December 2016, TB advocates congratulated the Fund on its commitment to invest an additional £50 million over the next five years in research and development to combat antimicrobial resistance (AMR), and encouraged the Fund to prioritize drug-resistant TB in its efforts.

Drug-resistant TB is the leading cause of AMR-related deaths - causing one in three. “ … tackling TB and drugā€resistant TB must be at the heart of any global action against AMR.”

The signatories requested a response by 16 January 2017.

To read the full letter, click here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By TB advocates

Published: Jan. 12, 2017, 8:48 p.m.

Last updated: Jan. 12, 2017, 9:49 p.m.

Print Share